EXAS vs GDRX Stock Comparison: AI Score, Valuation, Performance and Upside
EXAS provides cancer screening and diagnostic tests with a growing commercial infrastructure, while GDRX offers a prescription drug price transparency platform with an asset-light business model. Both are healthcare technology companies but serving very different parts of the patient journey.
EXAS vs GDRX compares two health technology companies at different points of their growth trajectories — Exact Sciences' diagnostics-driven cancer screening franchise versus GoodRx's consumer prescription price platform navigating PBM headwinds.
EXAS and GDRX are closely matched — they split the tracked metrics evenly.
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- Want exposure to the leading non-invasive colorectal cancer screening platform
- Believe Cologuard and next-generation cancer screening tests will continue taking market share
- See the large unscreened colorectal cancer patient population as a long-term growth opportunity
- Want exposure to a consumer healthcare price transparency platform with broad brand recognition
- See value in GoodRx's expansion into telehealth and pharmaceutical manufacturer programs
- Believe GoodRx's core economics will stabilize after recent PBM headwinds
| Metric | EXAS | GDRX |
|---|---|---|
| AI scorei | N/A | 23.6 |
| AI ranki | N/A | #3505 |
| Latest closei | N/A | $3.72 |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | EXAS | GDRX |
|---|---|---|
| 1Y ago | N/A | $11.41K (+14.1%) started 2025-11-04 |
| 5Y ago | N/A | $850.29 (-91.5%) started 2021-11-05 |
| 10Y ago | N/A | $736.63 (-92.6%) started 2020-09-23 |
Hypothetical — past performance does not guarantee future results.
| Metric | EXAS | GDRX |
|---|---|---|
| Market capi | N/A | $1.21B |
| Trailing P/Ei | N/A | 58.92 |
| Forward P/Ei | N/A | 9.92 |
| Price/Salesi | 6.17 | N/A |
| EV/Revenuei | N/A | 1.81 |
| Analyst targeti | N/A | $4.03 |
| Target upsidei | N/A | +14.02% |
| Metric | EXAS | GDRX |
|---|---|---|
| Revenue growthi | N/A | -1.30% |
| Earnings growthi | N/A | -44.50% |
| EPS growthi | N/A | -44.50% |
| FCF margini | N/A | +14.33% |
| Operating margini | N/A | 11.79% |
| Profit margini | N/A | 2.07% |
| ROIC proxyi | N/A | 2.52% |
| Return on equityi | N/A | 2.52% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.29 | 1.58 |
| Debt/equityi | N/A | 83.22 |
| Current ratioi | N/A | 1.38 |
| Quick ratioi | N/A | 0.42 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | EXAS | GDRX |
|---|---|---|---|
| 1Y | Growthi | N/A | +14.11% |
| CAGRi | N/A | +14.12% | |
| Volatilityi | N/A | 55.58% | |
| Sharpe ratioi | N/A | 0.44 | |
| Sortino ratioi | N/A | 0.63 | |
| Max drawdowni | N/A | 43.84% | |
| Current drawdowni | N/A | 2.11% | |
| Avg drawdowni | N/A | 18.25% | |
| Ulcer Indexi | N/A | 21.17% | |
| Max daily dropi | N/A | 18.78% | |
| Max wkly dropi | N/A | 24.29% | |
| 5Y | Growthi | N/A | -91.50% |
| CAGRi | N/A | -38.94% | |
| Volatilityi | N/A | 72.58% | |
| Sharpe ratioi | N/A | -0.38 | |
| Sortino ratioi | N/A | -0.54 | |
| Max drawdowni | N/A | 95.73% | |
| Current drawdowni | N/A | 91.50% | |
| Avg drawdowni | N/A | 83.35% | |
| Ulcer Indexi | N/A | 84.97% | |
| Max daily dropi | N/A | 38.91% | |
| Max wkly dropi | N/A | 47.48% | |
| 10Y | Growthi | N/A | -92.63% |
| CAGRi | N/A | -34.73% | |
| Volatilityi | N/A | 70.97% | |
| Sharpe ratioi | N/A | -0.31 | |
| Sortino ratioi | N/A | -0.44 | |
| Max drawdowni | N/A | 96.73% | |
| Current drawdowni | N/A | 93.49% | |
| Avg drawdowni | N/A | 76.22% | |
| Ulcer Indexi | N/A | 80.66% | |
| Max daily dropi | N/A | 38.91% | |
| Max wkly dropi | N/A | 47.48% |
| Category | EXAS | GDRX |
|---|---|---|
| Company | Exact Sciences Corporation | GoodRx Holdings, Inc. |
| Sector | Health Care - Diagnostics | Healthcare |
| Industry | N/A | Health Information Services |
| Core business | Exact Sciences provides non-invasive cancer screening and diagnostic tests, led by Cologuard (colorectal cancer screening stool DNA test) and Oncotype DX (tumor profiling tests for breast, colon, and prostate cancer treatment decisions). | GoodRx provides a consumer-facing digital platform for comparing and accessing discounted prescription drug prices across U.S. pharmacies, allowing uninsured and underinsured patients to pay less than list price for their medications. |
| Investor focus | Investors track Cologuard's customer growth and revenue, anticipated next-generation Cologuard screening test launch, and Oncotype DX precision oncology testing volume. | Investors track GoodRx's monthly active consumer growth, prescription revenue (from pharmacy PBM spread), and expansion into newer healthcare services including telehealth and pharmaceutical manufacturer programs. |
- Cologuard is the leading non-invasive colorectal cancer screening test with Medicare coverage and broad physician adoption
- Oncotype DX provides genomic test results that guide chemotherapy decisions in breast cancer
- Large addressable market as colorectal cancer screening compliance remains below clinical guidelines
- Leading consumer brand for prescription drug price comparison in the U.S.
- Asset-light business model connecting consumers, pharmacies, and pharmacy benefit managers
- Expanding beyond prescription discounts into telehealth and manufacturer direct-to-patient programs
- Cologuard faces competition from Guardant Health's Shield blood-based colorectal cancer screening test
- High operating expenses relative to revenue have kept Exact Sciences unprofitable despite strong Cologuard revenue growth
- Next-generation Cologuard must maintain superiority as competing approaches improve
- Core prescription discount business has faced revenue headwinds from PBM (pharmacy benefit manager) changes affecting discount spread economics
- Growth has moderated significantly from COVID-era highs
- Competition from Amazon Pharmacy, Blink Health, and other prescription discount platforms
Compare more than two at a time
This page is a fixed writeup on EXAS and GDRX. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside EXAS and GDRX, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.